The latest medical insurance reimbursement policy for lxazomib

Ixazomib is an oral proteasome inhibitor used to treat multiple myeloma (Multiple Myeloma), a malignant bone marrow cancer that primarily affects plasma cells in the bone marrow. Ixazomib is a targeted therapy whose mechanism of action involves inhibiting proteasome function, thereby reducing the growth and proliferation of abnormal plasma cells.

The original drug of Ixazomib has been launched in China and has been included in medical insurance. Patients can purchase it domestically, but the price is still relatively high. The price is about 15,000 to 6,000 yuan. For specific prices and medical insurance reimbursement policies, please consult the local hospital pharmacy or medical insurance bureau. Foreign original drugs are even more expensive. The cheaper foreign ones are ixazomib generics, mainly Laotian generics. The price is more than 1,000 yuan, and the ingredients of the original drugs and generic drugs are basically the same.

Ixazomib is an oral medication, which is very convenient for patients and avoids the need for intravenous injections. Ixazomib affects the metabolism and growth of cancer cells by inhibiting intracellular proteasome activity. This helps slow the progression of multiple myeloma.

Often, ixazomib is given with other medicines to make the treatment more effective. This combination treatment can be customized to the patient's specific situation. Ixazomib has been clinically tested and proven to have significant efficacy in patients with multiple myeloma, including prolonging survival and reducing symptoms such as pain.

Like other drugs, ixazomib may also cause some side effects, such as nausea, vomiting, diarrhea, fatigue, etc. Therefore, patients need to be closely monitored and managed for these side effects during treatment.